From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Vistry – profit warning as now ‘aware’ 9 developments cost projections “understated”, though also the causes are not currently fully ascertained!

By Steve Moore | Tuesday 8 October 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Following the first half of 2024, emphasising “a strong half year performance” including its “Partnerships model significantly outperforming the traditional housebuilding market”, shares in Vistry Group (VTY) responded higher and most recently closed at 1273p. A “Trading update” today though commences including noting that the group “has recently become aware” that within its South division the total full-life cost projections to complete 9 developments “have been understated by c. 10% of the total build costs”, though also including “it is important to note that the group as a whole has around 300 developments”, so what of a current more than 25% lower share price response to below 950p?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 18:06:38